Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

1.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.

N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.

PMID:
24869598
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Ibrutinib treatment of CLL: the cancer fights back.

Young RM, Staudt LM.

Cancer Cell. 2014 Jul 14;26(1):11-3. doi: 10.1016/j.ccr.2014.06.023.

PMID:
25026208
[PubMed - indexed for MEDLINE]
3.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

PMID:
24311722
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.

Brown JR.

Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. doi: 10.1007/s11899-012-0147-9. Review.

PMID:
23296407
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH.

J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8.

PMID:
23045577
[PubMed - indexed for MEDLINE]
Free Article
6.

Ibrutinib resistance in chronic lymphocytic leukemia.

Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, Racchumi J, Xu G, Wu H, Ma J, Steggerda SM, Coleman M, Leslie C, Wang YL.

N Engl J Med. 2014 Jun 12;370(24):2352-4. doi: 10.1056/NEJMc1402716. Epub 2014 May 28. No abstract available. Erratum in: N Engl J Med. 2014 Jun 26;370(26):2547. Perez, Alijandro R [corrected to Perez, Alexendar R].

PMID:
24869597
[PubMed - indexed for MEDLINE]
Free Article
7.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

PMID:
23782158
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Targeted therapies: ibrutinib resonates with us.

Villanueva MT.

Nat Rev Clin Oncol. 2014 Jul;11(7):380. doi: 10.1038/nrclinonc.2014.105. Epub 2014 Jun 17. No abstract available.

PMID:
24935013
[PubMed - indexed for MEDLINE]
9.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC.

Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10.

PMID:
24415539
[PubMed - indexed for MEDLINE]
10.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Davids MS, Brown JR.

Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. Review.

PMID:
24941982
[PubMed - indexed for MEDLINE]
11.

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL.

Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.

PMID:
24270740
[PubMed - indexed for MEDLINE]
12.

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Brown JR.

Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24. Review.

PMID:
23656200
[PubMed - indexed for MEDLINE]
13.

The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.

Bhatt V, Alejandro L, Michael A, Ganetsky A.

Pharmacotherapy. 2014 Mar;34(3):303-14. doi: 10.1002/phar.1366. Epub 2013 Dec 12. Review.

PMID:
24338680
[PubMed - indexed for MEDLINE]
14.

Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.

Dias AL, Jain D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):265-71. Review.

PMID:
24433470
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.

McDermott J, Jimeno A.

Drugs Today (Barc). 2014 Apr;50(4):291-300. doi: 10.1358/dot.2014.50.4.2133570. Review.

PMID:
24918646
[PubMed - indexed for MEDLINE]
16.

[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].

Wang M, Xu W, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):245-9. doi: 10.7534/j.issn.1009-2137.2014.01.049. Review. Chinese.

PMID:
24598688
[PubMed - indexed for MEDLINE]
17.

The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.

Molica S.

Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.

PMID:
24083545
[PubMed - indexed for MEDLINE]
18.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

PMID:
24881631
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

PMID:
24307721
[PubMed - indexed for MEDLINE]
Free Article
20.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

Burger JA, Buggy JJ.

Leuk Lymphoma. 2013 Nov;54(11):2385-91. doi: 10.3109/10428194.2013.777837. Epub 2013 Aug 28. Review.

PMID:
23425038
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk